I get asked about FDA's expedited programs more than almost any other regulatory topic. Usually the question comes from a CEO or CSO who heard that a competitor got Breakthrough Therapy Designation and wants to know if they can get it too. The answer is almost always "maybe, but probably not for the reasons you think, and it doesn't do what you think it does."
FDA has four expedited programs. They're distinct. They can be combined. They each do different things. And none of them lets you skip the nonclinical safety package.
The confusion between them is real and the consequences are strategic — misallocated time, misplaced expectations, and occasionally a failed designation request that burns credibility with the review division. I'm going to spend the most time on Breakthrough Therapy because that's the one people actually ask about. The others I'll cover more briefly.
The four programs at a glance
| Program | What it does | When to apply | Eligibility |
|---|---|---|---|
| Fast Track | More frequent FDA meetings, rolling review | Pre-IND or anytime during development | Serious condition + unmet medical need |
| Breakthrough Therapy | All Fast Track features + intensive FDA guidance, organizational commitment | After preliminary clinical evidence | Serious condition + substantial improvement over existing therapy |
| Accelerated Approval | Approval based on surrogate endpoint | At NDA/BLA | Serious condition + unmet need + surrogate endpoint reasonably likely to predict benefit |
| Priority Review | 6-month review instead of 10-month | At NDA/BLA submission | Significant improvement in safety or effectiveness |
Fast Track
Section 506(b) of the FD&C Act. FDA guidance on expedited programs (2014).
Fast Track is the workhorse of the four programs. Eligibility bar is relatively low — serious or life-threatening condition, unmet medical need — and most drugs in development qualify. You apply at the pre-IND stage or anytime during development. FDA responds within 60 days.
What you get: more frequent FDA meetings (beyond the standard pre-IND, end-of-Phase 1, end-of-Phase 2, pre-NDA schedule), rolling review of your NDA/BLA (submit completed sections as they're ready instead of all at once — saves 2-4 months), and eligibility for the other expedited programs. What you don't get: a lower approval bar, fewer nonclinical studies, faster IND review. The 30-day safety review is the same whether you're Fast Track or not.
If your drug targets a serious condition, apply. The rolling review benefit alone is worth the paperwork, and the additional meeting opportunities are especially valuable for first-time sponsors who don't yet have a working relationship with their review division.
Breakthrough Therapy Designation (BTD)
Section 506(a) of the FD&C Act, added by FDASIA in 2012. This is the one everyone wants. It's also the one that matters most for small biotechs, and the one most commonly misunderstood.
Breakthrough designation is the one that actually changes the dynamic between you and FDA. Fast Track gives you more meetings. BTD gives you a different kind of meeting. A cross-disciplinary FDA team works with you to design your development program — not reviewing what you submit, but actively shaping what you should submit. Senior management gets involved. Trial designs that would normally require extensive negotiation (smaller trials, adaptive designs, biomarker-based endpoints) become possible because the review division is invested in getting your drug through efficiently.
I talked to a regulatory VP at a rare disease biotech last year who described the pre-BTD and post-BTD experience as "night and day." Before designation, standard interactions — submit, wait, get comments, revise. After designation, the FDA team proactively flagged potential issues in their development plan and suggested solutions. "It felt like they were on our team," she said. I think that's the right frame. BTD doesn't lower the bar. It puts FDA on your side of the table while you figure out how to clear it.
The catch: you need preliminary clinical evidence of substantial improvement over existing therapies. Both terms are specific. Clinical evidence means human data — Phase 1 or early Phase 2. Animal model efficacy doesn't count. Substantial improvement means clinically meaningful, not just statistically significant: higher response rate, longer survival, activity in patients who failed everything else. Something a doctor would call better, not just something a statistician would.
FDA grants about 30-40% of BTD requests. The most common denial reason: the clinical data doesn't show substantial improvement. Companies submit with preclinical data only, or with Phase 1 pharmacokinetic data showing the drug is active but not clearly superior. Both get denied.
Don't submit a weak BTD request to "see what happens." A denial doesn't formally penalize you, but it signals to the review division that you may not understand the competitive landscape in your indication. That's a first impression you don't want to make.
Your nonclinical package, by the way, doesn't change. Safety pharmacology core battery, genotoxicity battery, repeat-dose tox — all still required. BTD changes how FDA works with you on the clinical side. It doesn't exempt you from anything on the nonclinical side.
Accelerated Approval
This one is fundamentally different. Fast Track and BTD change how FDA works with you during development. Accelerated Approval changes the basis on which your drug gets approved — Section 506(c) of the FD&C Act, 21 CFR Part 314, Subpart H for drugs, Part 601, Subpart E for biologics.
Instead of proving your drug improves survival or prevents disease progression (which can take years to measure), you demonstrate an effect on a surrogate endpoint — ORR in oncology, CD4 count in HIV, LDL reduction in cardiovascular disease — and get approved based on that. Then you conduct confirmatory trials post-approval.
The "then" in that sentence is doing a lot of work. Post-marketing confirmatory trials are mandatory, and under the FDORA provisions (2022), FDA has streamlined authority to withdraw Accelerated Approvals when those trials fail. This has happened — multiple oncology drugs lost their approvals between 2021-2025 when confirmatory data didn't pan out. The current FDA posture is more enforcement-forward than anything in the program's history. Sponsors must have confirmatory trial protocols agreed upon before approval and must report progress.
Your nonclinical package doesn't change under Accelerated Approval. All M3(R2) requirements apply. What changes is on the clinical side: surrogate endpoint instead of hard clinical outcome. If your Phase 2 data shows a strong surrogate signal, raise the Accelerated Approval discussion at your end-of-Phase 2 meeting.
Priority Review
Four fewer months of waiting. That's what Priority Review gives you — 6-month review instead of 10-month, per PDUFA. Your NDA/BLA must offer a significant improvement in safety or effectiveness for a serious condition. FDA makes this determination at filing. You can request it in the cover letter, but the real determinant is the data. Fast Track and BTD both make you eligible. Neither guarantees it.
Combining programs
The four programs aren't mutually exclusive. A drug can have Fast Track designation, Breakthrough Therapy Designation, and receive Priority Review of an NDA submitted under the Accelerated Approval pathway. Some drugs have gotten all four.
The typical progression for a strong program:
- Pre-IND or Phase 1: Request Fast Track designation
- Phase 1/2 with strong early data: Request Breakthrough Therapy Designation
- End of Phase 2: Discuss Accelerated Approval pathway with FDA
- NDA submission: Request Priority Review
Not every drug will qualify for all four. Most won't qualify for BTD. But mapping out the designation strategy early helps you plan your development timeline and investor communications.
What none of this changes
I've seen companies assume that a designation somehow reduces their nonclinical burden. It doesn't. ICH M3(R2) requirements — repeat-dose tox in two species, safety pharmacology core battery, genotoxicity battery, ADME — apply regardless of whether you're Fast Track, Breakthrough, or neither. The 30-day IND safety review is the same. GLP requirements per Part 58 are the same.
The only nonclinical flexibility that exists comes from ICH S9 for anticancer drugs — and that's based on the patient population and therapeutic area, not on any designation.
Which one do you actually need?
If you're not sure, start with Fast Track. Lowest bar, broadest benefit, doesn't preclude anything else. BTD comes later, when you have clinical data worth showing. Accelerated Approval and Priority Review are NDA-stage conversations.
The mistake I see most often: spending months on designation strategy when the nonclinical package isn't ready. No designation exempts you from ICH M3(R2). No designation shortens the 30-day IND review. The programs change how FDA works with you and how fast they review your NDA. They don't change what you need to submit. If your preclinical program has gaps, a Breakthrough Therapy Designation won't fill them.
One more thing — I've noticed that companies pursuing BTD sometimes under-invest in the pre-IND meeting. The pre-IND meeting is available to everyone, regardless of designation status, and it gives you direct FDA feedback on your nonclinical program design. If you're a first-time sponsor, the pre-IND meeting is arguably more valuable than any designation you'll get later.
Related reading:
- FDA IND Submission Checklist 2026 — complete IND requirements by CTD module
- Pre-IND Meeting with FDA: How to Prepare — getting early FDA feedback
- Nonclinical Overview guide — understanding what goes in your IND is more important than which designation you get